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Abstract 
Despite significant diagnostic and therapeutic advances, heart failure (HF) is linked with high 
mortality and morbidity. Hospitalization for decompensated HF is still the most common 
cause of hospitalization in adults. What is more, a particularly high risk of hospitalization 
(even up to 50% of patients) is observed within a few months after a previous HF 
hospitalization. Sacubitril/valsartan, a first-in-class drug, contains a neprilysin inhibitor 
(sacubitril) and an angiotensin II receptor blocker (valsartan). In PARADIGM-HF trial 
investigators showed, that sacubitril/valsartan significantly reduced primary endpoint 
combined with cardiovascular death or HF hospitalization in patients with chronic, 
symptomatic HF (New York Heart Association class II–IV) with reduced ejection fraction 
(left ventricular ejection fraction [LVEF] ≤ 35–40%). Recently, results of the PIONEER-HF 
trial, which included HF patients with LVEF ≤ 40% who were hospitalized for acute 
decompensated HF were also published. The study proved that early, in-hospital, 
implementation of sacubitril/valsartan in these patients resulted in a substantially greater 
reduction of N-terminal prohormone B-type natriuretic peptide concentration and a lower rate 
of HF rehospitalizations with similar safety profile for enalapril. 
Key words: sacubitril/valsartan, acute decompensated heart failure, angiotensin 
receptor neprilysin inhibitor, angiotensin receptor neprilysin inhibitors (ARNI) 
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Introduction 
Management of heart failure (HF) is one of the most important challenges of modern 
medicine in highly developed countries [1]. An aging population, effective invasive treatment 
of coronary artery disease and the advancement of new pharmacological molecules which 
improve the prognosis of patients with cardiovascular diseases could explain the increase in 
HF prevalence [2, 3]. This is linked to the high costs of healthcare, which are mainly resulting 
from multiple hospitalizations due to worsening HF, as well as high mortality and poor 
quality of life (Fig. 1) [1, 3, 4].  
Heart failure is a complex and progressive clinical syndrome caused by abnormalities 
of cardiac structure or function leading to inadequate cardiac output to fulfill metabolic 
demands or adequate cardiac output with increased left ventricular filling pressure [2]. There 
are multiple etiologies of HF, but it has been established that finally the same 
pathophysiological mechanisms are involved in the clinical progression of HF. The 
pathophysiology is based on progressive neurohormonal activation, involving two key 
systems: the renin–angiotensin–aldosterone system (RAAS) and the sympathetic nervous 
system (SNS). These mechanisms under physiological conditions are essential in the 
regulation of cardiovascular homeostasis in order to maintain proper cardiac function and 
perfusion of vital organs [5]. However, prolonged activation of these systems accelerates the 
progression of HF and promotes organ damage. Stimulation of the RAAS increases sodium 
and water retention, blood pressure, and also leads to fibrosis and remodeling of the 
myocardium and endothelial dysfunction with the formation and destabilization of 
atherosclerotic plaques. Activation of the SNS results in vasoconstriction, increased heart rate 
and myocardial contractility [5]. 
In recent guidelines HF was classified into three subtypes — HF with reduced ejection 
fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and HF mid-range ejection 
fraction (HFmrEF), according to the ejection fraction, natriuretic peptide levels and the 
presence of structural heart disease and diastolic dysfunction [2]. Differentiation of the HF 
subtype has important clinical and prognostic implications, as is a commonly accepted 
management with proven beneficial effects on prognosis, quality of life and acceptable safety 
profiles concerning patients with HFrEF [2]. However, patients with HFpEF and HFrEF have 
similarly high mortality risk and rate of rehospitalization after discharge [6, 7]. There are 
currently two interesting on-going studies on patients with HFpEF — PARAGON-HF 
(Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with ARB Global 
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Outcomes in HF with preserved ejection fraction) and PARALLAX (A Randomized, Double-
blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF 
Patients) will investigate the benefits of sacubtril/valsartan in patients with HFpEF [8, 9]. 
In this review, discussion focuses on the current role of sacubitril/valsartan in the 
management of patients with acute decompensated HFrEF, with particular regard to results 
from the PIONEER-HF and other recent studies. 
 
Current HFrEF treatment 
From almost two decades treatment of chronic HF have used angiotensin converting 
enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) and beta-blockers, followed 
by the implementation of mineralocorticoid receptor antagonists and ivabradine into clinical 
practice [2]. While symptomatic management is covered mainly by diuretics [2]. An 
important headway in the treatment of HFrEF in recent years was the development of a new 
drug containing a combination of valsartan and sacubitril, belonging to the angiotensin 
receptor neprilysin inhibitors (ARNI) [10]. 
In patients with acute decompensated HF the main part of management consists of 
improving patient signs and symptoms, correction of volume overload, improvement of 
hemodynamic status and counteracting the neurohormonal hyperactivation [2, 5]. The key 
drugs in HF therapy in the acute setting are intravenous diuretics, vasodilators, and less 
commonly inotropic agents [2]. Nevertheless, despite rapid and aggressive initiation of 
therapy, long-term prognosis of patients with acute HF remain very poor. Therefore, there is a 
need for seeking for new and better therapeutic strategies to improve outcomes. 
 
Sacubitril/valsartan  
Sacubitril/valsartan is a first-in-class ARNI. This drug has a class I indication for 
treatment of symptomatic HFrEF in the current European and American guidelines [2, 11]. 
The mechanism of action of this novel therapy includes RAAS inhibition through AT1 
receptor blockade (valsartan) and neprilysin inhibiton (sacubitril), which increases levels of 
endogenous vasoactive peptides [12].  
Besides the harmful activity of RAAS and SNS systems, other counter-regulatory 
pathways are activated in HF, including the natriuretic peptide (NP) system [13]. Sacubitril by 
inhibition of neprilysin reduces degradation of NP, bradykinin and other peptides. As a 
consequence, increased concentrations of mainly type A circulation (ANP) and type B 
natriuretic peptides (BNP) increases diuresis, natriuresis, and improves vasodilatation and 
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relaxation of the myocardium. ANP and BNP also inhibits the secretion of renin and 
aldosterone. The selective blocking of the AT1 receptor reduces vasoconstriction, sodium and 
water retention and cardiac hypertrophy [6, 12–14]. 
 
The PARADIGM-HF trial  
The PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin 
Inhibitor with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global 
Mortality and Morbidity in Heart Failure) trial revealed that sacubitril/valsartan brings 
significant benefits among ambulatory patients with HFrEF compared with the use of RAAS 
inhibitor alone. Compared with enalapril, sacubitril/valsartan reduced by 20% the composite 
endpoint of cardiovascular death or HF hospitalization, giving a real chance for further 
improvement in HF therapy. Because of these results, the trial was stopped early after a 
median follow up of 27 months [10, 15]. In consequence, sacubitril/valsartan received a 
strong recommendation in the European and American guidelines as an alternative for 
ambulatory HFrEF patients who tolerate an ACEI or ARB and are still symptomatic [2, 11]. 
 
The PIONEER-HF trial — study design 
There is limited data on sacubitril/valsartan in an acute setting, such as in patients 
hospitalized for acute decompensated HF and patients with severe symptomatic chronic HF. 
However, it seems reasonable to initiate and intensify lifesaving chronic therapy already in 
the hospital to decrease the risk of premature HF re-exacerbation. The goal of the PIONEER-
HF (Comparison of Sacubitril/Valsartan versus Enalapril on Effect on NT-proBNP in Patients 
Stabilized from an Acute Heart Failure Episode) trial was to assess the safety and efficacy of 
sacubitril/valsartan use in hospitalized individuals with acute decompensated HFrEF [16]. 
Interestingly, the PIONEER-HF trial was construed early after the appearance of positive data 
from the PARADIGM-HF study. As a rationale for conducting this trial, the researchers 
highlighted that in the PARADIGM-HF approximately 40% of participants had no previous 
HF hospitalization, and at most 15% of patients were hospitalized for a primary diagnosis of 
HF during the entire study [15]. What is more, patients with actual acute decompensated HF 
were excluded from the PARADIGM-HF study and only less than 1% of patients had New 
York Heart Association (NYHA) class IV symptoms at baseline [15]. 
In the PIONEER-HF trial 881 patients were recruited with HFrEF (≤ 40%), currently 
hospitalized for acute decompensated HF with elevated NP levels (N-terminal pro–B-type 
natriuretic peptide [NT-proBNP] ≥ 1600 pg/mL or BNP ≥ 400 pg/mL). The randomization 
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was not earlier than 24 h and up to 10 days from hospital admission. The patients had to be 
clinically stable. Inclusion and exclusion criteria from the PIONEER study are presented in 
Table 1. After achieving hemodynamic stabilization, the patients were randomized 1:1 to 
sacubitril/valsartan (n = 440) or enalapril (n = 441), and were then followed for 8 weeks. 
Initial dose of sacubitril/valsartan was 24/26 or 49/51 mg, and for enalapril was 2.5 or 5 mg, 
both given twice daily. If the conversion was made from ACEI, there was a 36-h wash-out 
period. The investigators aimed to up-titrate the dose of sacubitril/valsartan to 97/103 mg and 
enalapril to 10 mg twice daily. Finally, they selected a surrogate biomarker (NT-proBNP) as 
the primary endpoint. The primary efficacy outcome was a change in NT-proBNP 
concentration from baseline to week 4 and week 8 [16]. Secondary efficacy and safety 
outcomes are listed in Table 2.  
 
Results of the PIONEER-HF trial 
In the PIONEER-HF trial mean age of patients was 61 years, 72% were male and 36% 
were black. At randomization, the median systolic blood pressure was 118 mm Hg, and NT-
proBNP concentration at screening was 4812 pg/mL. The median left ventricular ejection 
fraction (LVEF) was 24%; two thirds of patients had NYHA class III, and approximately 10% 
had NYHA class IV. The median serum creatinine was 1.3 mg/dL; and serum potassium was 
4.2 mmol/L. Further, approximately two thirds of patients had previously beem diagnosed 
with HF and 60% had at least one HF hospitalization within the previous year. At the time of 
randomization 61.7% of the patients had peripheral edema, 32.9% had rales on lungs 
auscultation and 93.0% received intravenous furosemide during the index hospitalization 
before randomization. Fifty-two percent of the patients were not receiving an ACEI or ARB 
at the time of hospital admission [16].  
In the PIONEER-HF treatment with sacubitril/valsartan was associated with a greater 
time-averaged reduction in NT-proBNP concentration (primary efficacy outcome) compared 
to enalapril. The investigators also noted a 25.3% and 46.7% reduction in NT-proBNP 
concentration in enalapril and sacubitril/valsartan groups, respectively. This reduction was 
observed within the first week after drug initiation [16]. NT-proBNP is a biomarker of 
neurohormonal activation and hemodynamic stress, which plays an important role as a tool 
for HF diagnosis, monitoring of therapy and prognosis. It is worth noting, that HFrEF patients 
with concomitant atrial fibrillation (AF) have higher concentration of NT-proBNP. However, 
Kristensen et al. [17] showed that NT-proBNP > 400 pg/mL in those patients had a similar 
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value in the prediction of cardiovascular outcomes comparing to HF patients without AF [17, 
18]. 
The PIONEER-HF study also observed a reduction in high-sensitive troponin T 
concentration in the sacubitril/valsartan group (p < 0.05). Elevation of troponin is a very 
frequent finding in patients hospitalized for acute decompensated HF and is associated with 
poor outcomes during hospitalization and increased risk of death or rehospitalizations after 
discharge [19]. Nakou et al. [20] already showed that troponin I concentrations may be an 
independent predictive marker of a sacubitril/valsartan positive response in HFrEF. 
Importantly, the PIONEER-HF study also showed a 44% reduction in HF 
rehospitalizations and 46% reduction in a composite outcome of serious clinical events 
(death, HF rehospitalization, need for a left ventricular assist device, or heart transplant). 
What is more, previously, Desai et al. [21] showed that patients treated with 
sacubitril/valsartan comparing to enalapril in the PARADIGM-HF study had less frequent 30-
day readmissions for any cause after HF hospitalization. The results of these studies 
encourages early use of sacubitril/valsartan and gives an opportunity for additional 
improvement of outcomes of HF patients compared to enalapril. The results of the clinical 
and safety outcomes of the PIONEER-HF study are presented in Tables 3 and 4. 
In the PIONEER-HF study, patients hospitalized for acute coronary syndrome with 
concomitant signs of HF were excluded from the study. However, an on-going PARADISE-
MI (Prospective ARNI vs. ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart 
Failure Events After MI) study enrolls patients with LVEF < 40%, and signs of HF in the 
post-acute myocardial infarction phase (without prior chronic HF). The PARADISE-MI study 
was designed to evaluate benefits of sacubitril/valsartan versus ramipril in reducing the 
occurrence of composite endpoint of cardiovascular death, HF hospitalization and outpatient 
HF occurrence in patients with new-onset HF after recent myocardial infarction [22].  
 There are also other studies evaluating the process of initiation and uptitration of 
sacubitril/valsartan following hospitalization for acute decompensated HF. The rationale of 
the TRANSITION (The Comparison of Pre- and Post-discharge Initiation of LCZ696 
Therapy in HFrEF Patients After an Acute Decompensation Event) study was to evaluate 
efficacy and safety of in-hospital initiation of sacubitril/valsartan in HFrEF patients 
hospitalized for acute decompensated HF after clinical stabilization [23]. According to the 
protocol, patients were randomized within ≥ 24 h after hemodynamic stabilization (in a pre-
discharge arm) or up to 14 days after discharge (a post-discharge arm). The study enrolled 
patients with deterioration of chronic HF or with de novo acute decompensated HF, as well as 
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patients with or without previous ACEI/ARB therapy [24]. The primary results of the 
TRANSITION study demonstrated that uptitration of sacubitril/valsartan to a target dose 200 
mg (sacubitril 97 mg and valsartan 103 mg twice daily) was achieved in about 45% of 
patients who started taking the drug before discharge, compared with 50% of patients who 
started the drug after discharge. The difference was not statistically significant. Adverse 
events prompting discontinuations of sacubitril/valsartan therapy were rare, and occurred 
similarly in both arms of the trial [24]. 
The PARADIGM-HF study recruited patients who were pre-exposed to optimal doses 
of enalapril (10 mg twice daily) and were then transitioned to sacubitril/valsartan (first 100 
mg (sacubitril 49 mg and valsartan 51 mg), twice daily, and then sacubitril/valsartan 200 mg 
(sacubitril 97 mg and valsartan 103 mg), twice daily, over a 6–8 week period before 
randomization. In comparison, the TITRATION (Safety and Tolerability of Initiating LCZ696 
in Heart Failure Patients) study was addressed to evaluate the tolerability of initiation/faster 
uptitration (condensed shorter 3-week and conservative 6-week uptitration) of 
sacubitril/valsartan in HF patients with LVEF ≤ 35%. The study population was comprised of 
498 in- and outpatients, both patients pre-exposed to varying doses of an ACEI/ARB and 
ACEI/ARB-naive. Initially, patients were taking 50 mg sacubitril/valsartan twice a day for 5 
days. The authors showed that sacubitril/valsartan was characterized by a good safety profile 
and tolerance regardless of time to reach the target dose. There were no statistically 
significant differences in the occurrence of hypotension, renal dysfunction, hyperkalemia and 
angioedema between ‘condensed’ vs. ‘conservative’ regimens. The secondary tolerability 
outcome was related to the number of patients who managed to reach the target dose 97/103 
mg twice daily and to maintain it for 12 weeks. Such therapeutic success was achieved in 
75.9% of the study participants (in 78% of people in the 3-week group and 84% in the 6-week 
group, p = 0.07). It may be concluded, based on the results of the TITRATION study that 
initiation/uptitration of sacubitril/valsartan from 50 to 200 mg twice daily had a good 
tolerability over the  3- and 6-week process, but more gradual uptitration may have fewer side 
effects and may be better tolerated in patients previously treated with low doses of ACEI or 
ARB (or ACEI/ARB naive) [25]. 
What is highly important in terms of drug initiation in the acute setting, was that the 
PIONEER-HF trial sacubitril/valsartan was well tolerated and showed a good safety profile. 
Rates of the key safety outcomes including symptomatic hypotension, worsening renal 
function, hyperkalemia, or angioedema were comparable between the two study arms (for all 
p-value > 0.05). In addition, all 6 cases of angioedema in the enalapril group occurred in 
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black patients, while the only case in the sacubitril/valsartan group was in a white patient. 
Trial medication was discontinued in approximately 20% of patients in both groups [16]. In 
contrast, in the PARADIGM-HF study, hypotension was more frequent in the 
sacubitril/valsartan group, while hyperkalemia, higher serum creatinine level, need for 
discontinuation of the study drug because of renal impairment and cough were more common 
in the enalapril group (for all p-value > 0.05). Sacubitril/valsartan was discontinued in 17.8% 
and enalapril in 19.8% of patients (p = 0.02) [15]. 
Luo et al. [26] assumed that implementation of the novel therapy with ARNI into the 
clinical practice is slow and they were seeking characteristics of early adopters and factors 
associated with ARNI prescription among patients discharged after acute HF hospitalization. 
They analyzed 16674 HFrEF patients hospitalized in 210 hospitals from October 2015 to 
December 2016. ARNI was prescribed at discharge for 6.1% of them. They showed that for-
profit hospitals located in the Northern United States had significantly higher odds of ARNI 
prescription compared with not-for-profit hospitals located in the Western United States (p = 
0.04 and p = 0.02, respectively) [26]. Further studies assessing sacubitril/valsartan will 
perhaps translate into a better understanding of the new evidence-based therapy and minimize 
differences across hospitals. 
New evidence regarding the use of sacubitril/valsartan in patients hospitalized for 
new-onset HF or decompensated chronic HF sacubitril/valsartan was included in the 
European Society of Cardiology 2019 experts’ clinical practice update on HF [27]. According 
to this new document sacubitril/valsartan, rather than an ACEI or an ARB, may be considered 
in these patients to reduce short-term risk of adverse outcomes. The direct introduction of 
sacubitril/valsartan, without the need of overtaking ACEI titration, significantly facilitates 
management of HF patients. 
Authors of the PIONEER-HF trail pointed out some limitations of the study. They 
concluded that there was a need to wait for hemodynamic stability and a 36-h wash-out period 
in the sacubitril/valsartan group, with 6 h of obligatory observation, may require prolonged 
hospital stays. However, the median duration of the index hospitalization (5.2 days) was 
shorter than was shown in a previous analysis from the registry of European Society of 
Cardiology (median hospital stay was 7 days) [28]. Additionally, there was high 
discontinuation rate of study drug in both arms and 15% had missing data for the primary 
endpoint [16]. 
 
Conclusions 
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The results of the presented studies encourage the early initiation of 
sacubitril/valsartan treatment immediately after achieving clinical stabilization to improve 
outcomes of HF patients after hospitalization for worsening HF. Treatment of clinically 
stabilized HFrEF patients hospitalized for acute decompensated HF with sacubitril/valsartan 
significantly reduces NT-proBNP concentrations and the risk of serious clinical events. An 
early start of treatment with sacubitril/valsartan has a good safety profile and is not associated 
with an increased risk of symptomatic hypotension, renal dysfunction, hyperkalemia, or 
episode of angioedema compared to enalapril.  
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Figure 1. Clinical course of heart failure: progressive, chronic disease punctuated by acute 
episodes of exacerbation (based on and modified [29]).  
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Table 1. Inclusion and exclusion criteria for the PIONEER-HF trial (based on [16]). 
Inclusion criteria Exclusion criteria 
Adults > 18 years of age with the capacity to 
provide written informed consent 
Currently taking sacubitril/valsartan or any use 
within the past 30 days 
Currently hospitalized for acute decompensated 
HF with symptoms and signs of fluid overload 
History of hypersensitivity, known or suspected 
contraindications, or intolerance to any of the 
study drugs, including ACEI, ARB, or 
sacubitril 
LVEF ≤ 40% within the past 6 months Patients with a known history of angioedema 
related to previous ACEI or ARB therapy 
Elevated NT-proBNP ≥1600 pg/mL or BNP ≥ 
400 pg/mL during current hospitalization 
Requirement of treatment with both ACEI and 
ARB 
Randomization not earlier than 24 h and up to 
10 days from hospital admission 
Estimated glomerular filtration rate < 30 
mL/min/1.73 m2 
Systolic blood pressure ≥ 100 mmHg for the 
preceding 6 h before randomization and 
absence of symptomatic hypotension 
Serum potassium > 5.2 mEq/L  
No increase (intensification) in intravenous 
diuretic dose within the last 6 h prior to 
randomization 
Known hepatic impairment or history of 
cirrhosis with evidence of portal hypertension 
No use of intravenous vasodilators within 6 h 
prior to randomization 
Acute coronary syndrome, stroke, TIA; cardiac, 
carotid, or other major cardiovascular surgery; 
percutaneous coronary intervention or carotid 
angioplasty, within the prior month 
No intravenous inotropic drugs 24 h prior to 
randomization 
Implantation of cardiac resynchronization 
therapy within the past 3 months or intent to 
place 
 Isolated right HF due to severe pulmonary 
disease 
 Documented untreated ventricular arrhythmia 
with syncopal episodes within the past 3 
months 
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 Presence of hemodynamically significant 
mitral, aortic, or hypertrophic obstructive 
cardiomyopathy 
 History of malignancy of any organ system 
(other than localized and resectable skin 
cancers) within the past year with a life 
expectancy of less than 1 year 
 Pregnant or nursing (lactating) women 
ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor blockers; BNP — type B 
natriuretic peptides; HF — heart failure; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal 
pro–B-type natriuretic peptide; TIA — transient ischemic attack 
 
 
Table 2. PIONEER-HF study end-points (based on [16]). 
Primary outcome Secondary efficacy and safety outcomes 
Time-averaged 
proportional change in 
NT-proBNP 
concentration [time 
frame: baseline, week 
4 and week 8] 
Key safety outcomes 
Number of patients with incidences of: 
▪ symptomatic hypotension 
▪ worsening renal function 
▪ hyperkalemia 
▪ angioedema  
 Secondary biomarkers outcomes 
Change from baseline in: 
▪ high sensitivity troponin T concentration 
▪ BNP concentration 
▪ ratio of BNP to NT-proBNP  
 Clinical outcomes: 
Time to first occurrence of composite of  
I. Death 
II. Hospitalization for worsening HF 
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III. Left ventricular assist device implantation 
IV. Listed for cardiac transplantation 
V. Unplanned visit for acute HF requiring intravenous diuretics 
VI. Increase in diuretic dose >50% 
VII. Use of an additional drug for HF 
BNP — B-type natriuretic peptide; HF — heart failure; NT-proBNP — N-terminal pro–B-type natriuretic 
peptide 
 
 
Table 3. Clinical and biomarker outcomes in the PIONEER-HF trial (based on [16]). 
Clinical outcomes 
Sacubitril/valsartan 
(n = 440) 
Enalapril (n = 
441) 
Hazard ratio 
(95% CI) 
Composite of clinical events 249 (56.6%)  264 (59.9%) 0.93 (0.78–1.10) 
Death 10 (2.3%)  15 (3.4%) 0.66 (0.30–1.48) 
Rehospitalization for HF 35 (8.0%)  61 (13.8%) 0.56 (0.37–0.84) 
Implantation of left 
ventricular assist device 
1 (0.2%) 1 (0.2%) 0.99 (0.06–15.97) 
Inclusion on the list for heart 
transplantation 
0 (0%) 0 (0%) NA 
Unplanned outpatient visit 
leading to use of intravenous 
diuretics 
2 (0.5%)  2 (0.5%) 1.00 (0.14–7.07) 
Use of additional drug for HF 78 (17.7%)  84 (19.0%) 0.92 (0.67–1.25) 
Increase in dose of diuretics 
of > 50% 
218 (49.5%) 222 (50.3%) 0.98 (0.81–1.18) 
Composite of serious clinical 
events: 
▪ death 
▪ rehospitalization for HF 
▪ implantation of a left 
ventricular device 
41 (9.3%)  74 (16.8%) 0.54 (0.37–0.79) 
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▪ inclusion on the list of 
patients eligible for heart 
transplantation 
Secondary biomarker 
outcomes  
  
Ratio of change 
(95% CI) 
Change in high-sensitivity 
troponin T concentration 
−36.6 (−40.8 to 
−32.0) 
−25.2 (−30.2 
to −19.9) 
0.85 (0.77–0.94) 
Change in BNP concentration −28.7 (−35.5 to 
−21.3) 
−33.1 (−39.5 
to −25.9) 
1.07 (0.92–1.23) 
Change in ratio of BNP to 
NT-proBNP 
35.2 (28.8 to 42.0) 
−8.3 (−3.6 to 
−12.7) 
1.48 (1.38–1.58) 
BNP — B-type natriuretic peptide; CI — confidence interval; HF — heart failure; NA — not available, NT-
proBNP — N-terminal pro–B-type natriuretic peptide 
 
 
Table 4. Safety outcomes in the PIONEER-HF trial (based on [16]).  
Safety outcome 
Sacubitril/valsartan 
(n = 440) 
Enalapril (n = 
441) 
Relative risk 
(95% CI) 
Worsening renal function* 60 (13.6%) 65 (14.7%) 0.93 (0.67–1.28) 
Hyperkalemia 51 (11.6%) 41 (9.3%) 1.25 (0.84–1.84) 
Symptomatic hypotension 66 (15.0%) 56 (12.7%) 1.18 (0.85–1.64) 
Angioedema 1 (0.2%) 6 (1.4%) 0.17 (0.02–1.38) 
*Worsening renal function was defined by an increase in the serum creatinine concentration of 0.5 mg per 
deciliter or more (≥ 44 μmol/L) and a decrease in the estimated glomerular filtration rate of 25% or more; CI — 
confidence interval 
